Safer In Vitro Drug Screening Models for Melioidosis Therapy Development

Anna S. Amiss,¹ Jessica R. Webb,² Mark Mayo,² Bart J. Currie,^{2,3} David J. Craik,¹ Sónia Troeira Henriques,^{1,4*} and Nicole Lawrence^{1*}

¹Institute for Molecular Bioscience, The University of Queensland, Brisbane, Australia; ²Global and Tropical Health Division, Menzies School of Health Research, Darwin, Australia; ³Northern Territory Medical Program, Department of Infectious Diseases, Royal Darwin Hospital, Darwin, Australia; ⁴Queensland University of Technology, School of Biomedical Sciences, Institute of Healthy and Biomedical Innovation, and Translational Research Institute, Brisbane, Queensland, Australia

Abstract. Melioidosis is a neglected tropical disease caused by the Gram-negative soil bacterium *Burkholderia pseudomallei*. Current antibiotic regimens used to treat melioidosis are prolonged and expensive, and often ineffective because of intrinsic and acquired antimicrobial resistance. Efforts to develop new treatments for melioidosis are limited by the risks associated with handling pathogenic *B. pseudomallei*, which restricts research to facilities with biosafety level three containment. Closely related nonpathogenic *Burkholderia* can be investigated under less stringent biosafety level two containment, and we hypothesized that they could be used as model organisms for developing therapies that would also be effective against *B. pseudomallei*. We used microbroth dilution assays to compare drug susceptibility profiles of three *B. pseudomallei* strains and five nonpathogenic *Burkholderia* strains. *Burkholderia humptydooensis*, *Burkholderia thailandensis*, and *Burkholderia territorii* had similar susceptibility profiles to pathogenic *B. pseudomallei* that support their potential as safer in vitro models for developing new melioidosis therapies.

INTRODUCTION

Burkholderia pseudomallei is a Gram-negative bacterium that causes melioidosis,^{1,2} a neglected tropical disease, with one model estimating up to 165,000 cases and 89,000 deaths per year.¹ Mortality rates for infected individuals vary from under 10% in Darwin (Northern Territory, Australia),³ where state-of-the-art intensive care facilities are available, to more than 40% in endemic regions in Southeast Asia, where health resources are more limited.⁴

Conventional large-spectrum antibiotic classes, such as aminoglycosides (e.g., streptomycin, gentamicin, and kanamycin), early generation β -lactam antibiotics (e.g., penicillin), fluoroquinolones (e.g., ciprofloxacin), and macrolides (e.g., erythromycin), have little effect on *B. pseudomallei*, which limits treatment options.^{5–8} Importantly, environmental isolates and primary *B. pseudomallei* isolates are almost universally susceptible to the first-line drugs used for melioidosis therapy, ceftazidime, meropenem, and co-trimoxazole.^{5,9,10} However, the prolonged nature of melioidosis treatment (4–6 months) can lead to acquired antibiotic resistance, which is linked to treatment failure and mortality.⁹ To overcome both intrinsic and acquired antibiotic resistance, more efficacious therapies for melioidosis are required.^{1,11}

Efforts to develop new treatments for melioidosis are limited by the classification of *B. pseudomallei* as a risk group three microorganism (i.e., the potential to cause serious human disease) in most countries.^{12–15} This classification restricts its research to laboratories classified as biosafety level three in the United States,¹⁶ or the equivalent physical containment three in Australia and New Zealand.¹⁷ *Burkholderia pseudomallei* is also recognized as a tier one biothreat agent on the

Center for Disease Control and Prevention Bioterrorism Agent list,¹⁵ a classification that further restricts research efforts.^{18,19}

The use of nonpathogenic *Burkholderia* species as models for *B. pseudomallei* is a desirable approach for overcoming these limitations. *Burkholderia thailandensis*^{20–22} and mutant *B. pseudomallei* strains Bp82 and Bp190 that are avirulent to mice and hamsters²³ have been used as model organisms because of their close genetic relationship to *B. pseudomallei*, but extensive comparison of their susceptibility to antibiotics or other therapeutic compounds has not yet been described. In addition to these established models, we propose that other closely related *Burkholderia* species that are not implicated in human disease^{24–26} will also be useful model organisms for melioidosis research.

To determine their suitability as model organisms, we characterized the antibiotic susceptibility of five nonpathogenic *Burkholderia* strains and three *B. pseudomallei* strains to a panel of antibiotics and drug-like compounds. Here, we demonstrate that *B. thailandensis* and two newly characterized strains—*Burkholderia humptydooensis* and *Burkholderia territorii*—have susceptibility profiles that recapitulate *B. pseudomallei* susceptibility. The similarity of these profiles supports the utility of nonpathogenic *Burkholderia* as models for initial melioidosis therapy development.

MATERIALS AND METHODS

Burkholderia strains. *Burkholderia* strains used in this study were *B. pseudomallei* (MSHR10517, MSHR2154, and MSHR1364), *B. humptydooensis* (MSMB043), *Burkholderia oklahomensis* (MSMB0175), *Burkholderia stagnalis* (MSMB049), *B. thailandensis* (MSMB0608), and *B. territorii* (MSMB0110). These strains were collected and cultivated from soil or water samples as previously described (Menzies School of Health Research).^{27–29}

Antibiotic panel. Antibiotics that have been included in this study represent the current standard therapeutics for treating melioidosis, ceftazidime, co-trimoxazole, and meropenem⁵; and other antibiotics used to treat bacterial infections. To produce a wider susceptibility profile, antibiotics with varying levels of efficacy against *B. pseudomallei*^{7,30–36} were also included (see Table 1).

* Address correspondence to Nicole Lawrence, Institute for Molecular Bioscience, The University of Queensland, 306 Carmody Rd., Brisbane 4072, Australia, E-mail: n.lawrence@uq.edu.au or Sónia Troeira Henriques, Queensland University of Technology, School of Biomedical Sciences, Institute of Healthy and Biomedical Innovation, and Translational Research Institute, Brisbane, Queensland, 4102, Australia, E-mail: sonia.henriques@qut.edu.au.

TABLE 1
Minimum inhibitory concentrations of antibiotics against *Burkholderia* strains*

Minimum inhibitory concentrations of antimicrobials against <i>Burkholderia thailandensis</i>											
Antibiotic†	MIC (mg/L)‡										MIC90 (mg/L)
	<i>B. humphreysensis</i>	<i>B. oklahomensis</i>	<i>B. thailandensis</i>	<i>B. staghallis</i>	<i>B. territorii</i>	<i>B. pseudomallei</i> ¶					
	MSMB043	0175	MSMB0608	MSMB049	MSMB0110	MSHR1364	MSHR2154	MSHR10517	Various isolates from published reports		
Melioidosis	1–2 2–4 1	0.3 0.3–2 0.4–2	1–2 1 2	4 2–4 12–25	2 1 2	2 2 0.4	1–2 2 0.4	2 2 1	1–4 ^{31,32} 0.125–4 ³² 0.5–4 ^{31,32}	2–4 ^{7,30} – –	
Other antibiotics	Ceftazidime	> 35	> 35	> 35	> 35	> 35	–	–	–	> 128 ⁷	
	Co-trimoxazole	> 23	> 23	> 23	> 23	> 23	> 23	> 23	–	> 128 ^{7,34}	
	Meropenem	> 24	> 24	> 24	> 24	> 24	> 24	> 24	–	–	
	Ampicillin	> 16	8 to > 16	> 16	> 16	> 16	–	–	12.5–25 ³³	–	
	Sulfamethoxazole	5–9	1 to > 19	1	2–5	1	9	5–9	–	320 ³⁴	
	Trimethoprim	13	7	13	26–53	13	13	13	–	64 ³⁴	
	Rifampicin	7–15	15	15	> 15	7	> 16	> 16	> 50 ³³	8–32 ^{7,34}	
	Nalidixic acid	0.4–2	0.3–1	0.4	7–14	0.3–3	1	0.4–1	0.25–32 ³⁵	1–4 ^{7,34}	
	Doxycycline	2–7	1–28	2–14	2 to > 28	0.4–7	2	2	1.6–3.1 ³³	0.5–8 ^{30,34}	
	Tetracycline	3–10	5–10	5–10	10–21	–5	21	10–21	~6–20 ³³	16–32 ^{7,34}	
	Chloramphenicol	19–37	> 37	> 37	> 37	≥ 37	> 37	> 37	–	64 ³⁴	
	Kanamycin	> 37	> 37	> 37	> 37	> 37	> 37	> 37	> 50 ³³	64–128 ^{7,34}	
	Gentamicin	> 35	> 35	> 35	> 35	> 35	> 35	> 35	–	–	
	Purromycin	> 32	> 32	> 32	> 32	> 32	> 32	> 32	> 64 ³⁶	–	
	Spectinomycin	> 48	> 48	> 48	> 48	> 48	–	–	32–64 ³⁵	–	
	Clarithromycin	> 40	> 40	> 40	> 40	> 40	–	–	> 50 ³³	–	
	Paromomycin	> 47	> 47	> 47	> 47	> 47	–	–	> 50 ³³	–	
Streptomycin	> 47	> 47	> 47	> 47	> 47	–	–	> 50 ³³	–		

† *B. humphreysensis* = *Burkholderia humphreysensis*; *B. oklahomensis* = *Burkholderia oklahomensis*; *B. pseudomallei* = *Burkholderia pseudomallei*; *B. thailandensis* = *Burkholderia thailandensis*; *B. staghallis* = *Burkholderia staghallis*; *B. territorii* = *Burkholderia territorii*; *B. thallandensis* = *Burkholderia thallandensis*

* *B. humptydoensis* = *Burkholderia humptydoensis*; *B. oklahomensis* = *Burkholderia oklahomensis*; *B. pseudomallei* = *Burkholderia pseudomallei*; *B. thailandensis* = *Burkholderia thailandensis*; MIC = minimal inhibitory concentration.

† Antibiotics: Melioidosis, antibiotics currently used for treating melioidosis; Other antibiotics, used for treating bacterial infections.

‡ Minimal inhibitory concentrations were determined from 100% growth inhibition, using broth microdilution of bacteria in growth phase. Concentrations in µM were converted to mg/L. Data represent the MIC (or range) determined from at least three independent experiments (individual MIC data are shown in Supplemental Table S1).

§ Minimal inhibitory concentration 90 values indicate the concentration required to inhibit the growth of 90% of the tested population.

|| Minimal inhibitory concentration 90 values indicate the concentration required to inhibit the growth of 90% of the tested population.

¶ Antibiotics with previously reported high MICs for *B. pseudomallei* and high tested MICs for the near-neighbor strains were not tested against *B. pseudomallei* strains in this study.

FIGURE 1. Schematic representation of near-neighbor *Burkholderia* species and their relatedness to *Burkholderia pseudomallei* and other major disease-causing species. Relationships are derived from previous phylogenetic trees.^{24–26,43} Lines represent relationships between the species but not genetic distance. Closed circles indicate *Burkholderia* species included in this study. The species highlighted in bold are implicated in human disease.

Antibiotic susceptibility profiles. Antimicrobial susceptibility was tested using a plate-based broth microdilution method as before,³⁷ except that bacteria were incubated at 30°C because they showed better growth at 30°C than at 25°C and 37°C. In brief, assays were conducted in Mueller Hinton broth with bacteria in mid-log-phase growth that were diluted to $\sim 10^6$ colony-forming unit (CFU)/mL (optical density at 600 nm = 0.001). Serial dilutions of the compounds were then added to the bacteria (final density $\sim 5 \times 10^5$ CFU/mL). The minimal inhibitory concentration (MIC) was determined to be the lowest concentration of compound that inhibited visible bacterial growth 24 hours after treatment. Data represent the MIC determined from a minimum of three independent experiments for each strain (see Supplemental Table S1 for individual MIC data for all replicates). Principal component analyses were performed using the “prcomp” function, and plots were generated using the “ggplot” function of R version 4.0.0.³⁸

Medicines for Malaria Venture (MMV) Pathogen Box compound susceptibility profiles for *B. humptydooensis* and *B. territorii*. We tested the antimicrobial activity of the MMV Pathogen Box containing a library of 400 drug-like compounds.³⁹ Initial antimicrobial susceptibility testing was performed at 20 μ M against *B. humptydooensis* and *B. territorii*, using the methods described earlier. Ceftazidime (20 μ M) was added to each plate as a positive control for 100% growth inhibition.⁵ We identified a subset of compounds with promising activity (compound ID, molecular weight, molecular formula, and structure of compounds from this subset are provided in Supplemental Table S2). These compounds were serially diluted to determine the MIC toward *B. humptydooensis* and *B. territorii*. Data represent the MIC determined from three independent experiments for each strain.

RESULTS AND DISCUSSION

***Burkholderia* near-neighbor strains.** The *Burkholderia* genus comprises more than 70 species with varying virulence and pathogenicity,^{40–42} and these species can be divided according to their relationship to either *B. pseudomallei* (the *B. pseudomallei* complex) or *Burkholderia cepacia* (the *B. cepacia* complex). In the current study, we included three strains of *B. pseudomallei* and five representative near-neighbor *Burkholderia* strains of *B. thailandensis*, *B. humptydooensis*, *B. oklahomensis*, *B. stagnalis*, and *B. territorii*. The relationship between the non-pathogenic near neighbors and pathogenic *Burkholderia* species is represented in Figure 1. Genetic distance from *B. pseudomallei* is shown in Supplemental Table S3 for corresponding near-neighbor isolates from a previous study.⁴³

Antibiotic susceptibility profiles for *B. pseudomallei* and near neighbors. The aim of this investigation was to determine whether the antibiotic susceptibility of *B. pseudomallei* is recapitulated by near-neighbor species. We hypothesize that less pathogenic species with similar antibiotic susceptibility profiles to *B. pseudomallei* are useful as in vitro models to facilitate initial screening of new therapeutic molecules without the restrictive physical containment requirements required when working with *B. pseudomallei*.

We determined the susceptibility of the *B. pseudomallei* and near-neighbor strains to a panel of 20 antibiotics with previously reported MIC90 or MIC values against *B. pseudomallei*. The MICs (or MIC range) are compared in

FIGURE 2. Principal component analysis³⁸ of minimal inhibitory concentrations of antibiotics against *Burkholderia* strains: *Burkholderia pseudomallei* (Bp), *Burkholderia humptydooensis* (Bhu), *Burkholderia thailandensis* (Bth), *Burkholderia territorii* (Bte), *Burkholderia oklahomensis* (Bok), and *Burkholderia stagnalis* (Bst). (A) Analysis includes ceftazidime, co-trimoxazole, meropenem, trimethoprim, rifampicin, doxycycline, tetracycline, and chloramphenicol. (B) Exclusion of chloramphenicol from the analysis. The percentages of the total variance along the principal component 1 (PC1) and PC2 axes are shown in brackets.

Table 1 and show a similar overall susceptibility profile for all of the tested strains. Principal component analysis (PCA) of MICs from the eight most potent antibiotics—ceftazidime, cotrimoxazole, meropenem, trimethoprim, rifampicin, doxycycline, tetracycline, and chloramphenicol—revealed that *B. humptydooensis*, *B. thailandensis*, and *B. territorii* display a similar susceptibility to these antibiotics as *B. pseudomallei* strains MSHR10517, MSHR2154, and MSHR1364 (Figure 2A). The MICs of chloramphenicol for these *B. pseudomallei* strains may be considered as outliers, as they are at the higher end of the reported MIC range for *B. pseudomallei* (~6–20 mg/L). Indeed, removal of chloramphenicol MICs from the PCA analysis resulted in tighter clustering of *B. humptydooensis*, *B. thailandensis*, and *B. territorii* with *B. pseudomallei* (Figure 2B).

Minimal inhibitory concentrations for the antibiotics used to treat melioidosis were similar between near-neighbor *B. humptydooensis*, *B. thailandensis*, and *B. territorii* strains; *B. pseudomallei* strains from this study; and previously reported MICs for ceftazidime (1–2 mg/L), co-trimoxazole (2 mg/L), and meropenem (0.4–1 mg/L) against various *B. pseudomallei* strains (see Table 1). Minimal inhibitory concentrations for these antibiotics toward *B. oklahomensis* were slightly less predictive of *B. pseudomallei* susceptibility, and *B. stagnalis* MICs were even less predictive, especially for meropenem (MIC 12–25 mg/L).

The activity of other antibiotics used to treat bacterial infection further illustrated the utility of *B. humptydooensis*, *B. thailandensis*, and *B. territorii* as models for *B. pseudomallei*. Rifampicin had near-identical activity toward these near-neighbor strains and *B. pseudomallei* (MIC ~13 mg, see Table 1). Minimal inhibitory concentration ranges for doxycycline were similar between the near neighbors and *B. pseudomallei* (0.3–3 versus 0.4–1 mg/L), and the near neighbors were equally, or more, susceptible to trimethoprim (MIC 1–9 mg/L) and chloramphenicol (MIC 3–10 mg/L) than the *B. pseudomallei* strains (MIC 5–9 mg/L and 10–21 mg/L, respectively). Tetracycline susceptibility of the *B. pseudomallei* strains (MIC 2–4 mg/L) was within the range of MICs observed for *B. humptydooensis*, *B. thailandensis*, and *B. territorii*. The wider range of MICs observed for tetracycline (see Table 1, Supplemental Table S1) may reflect the bacteriostatic mechanism of action; however, this was not observed for other bacteriostatic antibiotics, including doxycycline and trimethoprim.

Kanamycin and nalidixic acid did not inhibit *B. pseudomallei* at the highest concentration tested (37 mg/L and 16 mg/L, respectively) but exhibited activity at these concentrations against *B. humptydooensis*, *B. oklahomensis*, *B. thailandensis*, and *B. territorii*. Finally, nine of the antibiotics—amoxicillin, ampicillin, cefsulodin, clarithromycin, gentamicin, spectinomycin, streptomycin, puromycin, and paromomycin—did not have activity against the tested *B. pseudomallei* and/or near-neighbor strains, consistent with previous reports of inactivity against various *B. pseudomallei* isolates^{7,33–36} (see Table 1).

These comparative antibiotic susceptibility screens showed that *B. pseudomallei* near neighbors *B. humptydooensis*, *B. thailandensis*, and *B. territorii* have similar antibiotic susceptibility profiles to those of *B. pseudomallei* against key melioidosis therapeutics, as well as other antibiotics (see Table 1, Figure 2).

Susceptibility of *B. humptydooensis* and *B. territorii* to MMV compounds. This study is the first report of antibiotic susceptibilities for *B. humptydooensis* and *B. territorii*. To further evaluate their suitability as models for predicting *B. pseudomallei* drug susceptibility, we also tested their susceptibility to 400 drug-like molecules from the MMV Pathogen Box.³⁹ These data allow independent comparison of MMV compound susceptibility of *B. humptydooensis* and *B. territorii* to five previously reported *B. pseudomallei* strains.⁴⁴

We initially tested MMV compounds at 20 µM (and identified five compounds with activity against *B. humptydooensis* and *B. territorii*). Four of these compounds—doxycycline, levofloxacin, rifampicin, and MMV688271—agreed with reported activity toward *B. pseudomallei*,⁴⁴ whereas MMV675968 is a newly identified active compound (see Supplemental Table S2 for compound characteristics). Next, we determined the MICs for these compounds against *B. humptydooensis* and *B. territorii* (see Table 2). The activities of doxycycline (MIC 0.5–1 mg/L), levofloxacin (MIC 1–6 mg/L), MMV688271 (MIC 4–8 mg/L), and ceftazidime (MIC 2–4 mg/L) against the near-neighbor strains were within 2-fold of their reported MICs against *B. pseudomallei* (1–3 mg/L, 4–10 mg/L, 6–12 mg/L, and 3–4 mg/L, respectively).⁴⁴ Minimal inhibitory concentrations for ceftazidime, doxycycline, and rifampicin determined from the MMV compound screen (Table 2) are in close agreement with MICs from the antibiotic susceptibility screen (Table 1). Principal component analysis of the MICs of these three antibiotics revealed that *B. humptydooensis*

TABLE 2

Minimal inhibitory concentrations of MMV Pathogen Box compounds against *B. humptydooensis* and *B. territorii* strains compared with five *B. pseudomallei* strains

Compound	MIC (mg/L)*		MIC (mg/L)†				
	<i>B. humptydooensis</i> MSMB 43	<i>B. territorii</i> MSMB 110	<i>B. pseudomallei</i> K96243	<i>B. pseudomallei</i> 576	<i>B. pseudomallei</i> NCTC13178	<i>B. pseudomallei</i> NCTC13179	<i>B. pseudomallei</i> MX2013
Ceftazidime‡	2–4	2–4	4	4	4	6	3
Doxycycline	0.4	0.3–1	1	2.5	3	2.5	2.5
Levofloxacin	1–6	1–3	4	10	6	6	6
Rifampicin	13	13–26	45	18	18	25	18
MMV688271	4–8	4–8	6	12	10	8	12
MMV675968	6–12	1	> 0.72§	> 0.72§	> 0.72§	> 0.72§	> 0.72§

B. humptydooensis = *Burkholderia humptydooensis*; *B. pseudomallei* = *Burkholderia pseudomallei*; *B. territorii* = *Burkholderia territorii*; MIC = minimal inhibitory concentration; MMV = Medicines for Malaria Venture.

* Minimal inhibitory concentration values for *B. humptydooensis* and *B. territorii* were determined from serial dilutions of the MMV Pathogen Box compounds, starting at 20 µM. Values were converted to mg/L. Data represent the MIC determined from three independent experiments.

† Minimal inhibitory concentration values for *B. pseudomallei* were determined by Ross et al.⁴⁴

‡ Ceftazidime was not part of the MMV panel but was included as a positive control with potent activity toward *B. pseudomallei*.

§ Inhibitory activity toward *B. pseudomallei* was not detected at the tested concentration of 2 µM (0.72 mg/L).⁴⁴

and *B. territorii* clustered with *B. pseudomallei* strains from this study, and four of the five *B. pseudomallei* strains were included in the Ross et al.⁴⁴ MMV compound study (see Supplemental Figure S1).

Newly identified compound MMV67968 showed activity toward *B. humptydooensis* and *B. territorii* with MICs (3–12 mg/L) that are less than MICs for rifampicin and only 2-fold higher than MICs for ceftazidime (2–6 mg/L), the “gold-standard” melioidosis therapy (see Table 2). Together, MMV compounds MMV688271 (Ross et al.⁴⁴ study) and MMV67968 (this study) may provide useful information for developing new drugs with activity toward *B. pseudomallei*.

In summary, newly characterized nonpathogenic *B. humptydooensis* and *B. territorii*, and previously described *B. thailandensis*, recapitulate the antibiotic susceptibility of pathogenic *B. pseudomallei* strains, including clinical strains of Mexican, Thai, and Australian origin (MMV compound comparison).⁴⁴ Therefore, each of these strains of nonpathogenic *Burkholderia* species has potential for use in high throughput in vitro screening of molecules for melioidosis therapy development.

The lower risk-group classification of the near-neighbor species allows expansion of melioidosis research into a wider landscape, where more laboratories have adequate facilities to perform the initial compound discovery. We are hopeful that inclusion of well-characterized and nonpathogenic model organisms in melioidosis research will accelerate the development of new treatment options for this neglected tropical disease.

Received April 6, 2020. Accepted for publication July 6, 2020.

Published online September 21, 2020.

Note: Supplemental figure and tables appear at www.ajtmh.org.

Acknowledgments: We would like to thank Alysha Elliot at the Institute for Molecular Bioscience, the University of Queensland, for her critical review of this work; Quentin Kaas at the Institute for Molecular Bioscience, the University of Queensland, for his support with the principal component analysis; Medicines for Malaria Venture for supplying the Pathogen Box compounds; and Vanessa Rigas at the Menzies School of Health Research for her laboratory support.

Financial support: This work was supported by funding from the Australian government (A. S. A. Research Training Program Scholarship), the Australian National Health and Medical Research Council (J. R. W., M. M., and B. J. C. grant numbers 1046812, 1098337, and 1131932, respectively, and the HOT NORTH Initiative; D. J. C., S. T. H., and N. L. grant number 1084965), and the Australian Research Council (Laureate Fellowship to D. J. C. [FL150100146] and Future Fellowship to S. T. H. [FT150100398]).

Authors' addresses: Anna S. Amiss, David J. Craik, and Nicole Lawrence, Institute for Molecular Bioscience, The University of Queensland, Brisbane, Australia, E-mails: a.bundock@imb.uq.edu.au, d.craik@imb.uq.edu.au, and n.lawrence@uq.edu.au. Jessica R. Webb and Mark Mayo, Global and Tropical Health Division, Menzies School of Health Research, Darwin, Australia, E-mails: jessica.webb@menzies.edu.au and mark.mayo@menzies.edu.au. Bart J. Currie, Global and Tropical Health Division, Menzies School of Health Research, Darwin, Australia, and Northern Territory Medical Program, Department of Infectious Diseases, Royal Darwin Hospital, Darwin, Australia, E-mail: bart.currie@menzies.edu.au. Sónia Troeira Henriques, Queensland University of Technology, School of Biomedical Sciences, Institute of Healthy and Biomedical Innovation, and Translational Research Institute, Brisbane, Queensland, 4102, Australia, E-mail: sonia.henriques@qut.edu.au.

REFERENCES

1. Limmathurotsakul D et al., 2016. Predicted global distribution of *Burkholderia pseudomallei* and burden of melioidosis. *Nat Microbiol* 1: 15008.
2. Wiersinga WJ, Currie BJ, Peacock SJ, 2012. Melioidosis. *N Engl J Med* 367: 1035–1044.
3. Currie BJ, Ward L, Cheng AC, 2010. The epidemiology and clinical spectrum of melioidosis: 540 cases from the 20 year Darwin prospective study. *PLoS Negl Trop Dis* 4: e900.
4. Limmathurotsakul D, Wongratnacheewin S, Teerawattanasook N, Wongsuvan G, Chaisuksant S, Chetchotisakd P, Chaowagul W, Day NP, Peacock SJ, 2010. Increasing incidence of human melioidosis in northeast Thailand. *Am J Trop Med Hyg* 82: 1113–1117.
5. Lipsitz R et al., 2012. Workshop on treatment of and postexposure prophylaxis for *Burkholderia pseudomallei* and *B. mallei* infection, 2010. *Emerg Infect Dis* 18: e2.
6. Dance D, 2014. Treatment and prophylaxis of melioidosis. *Int J Antimicrob Agents* 43: 310–318.
7. Thibault FM, Hernandez E, Vidal DR, Girardet M, Cavallo JD, 2004. Antibiotic susceptibility of 65 isolates of *Burkholderia pseudomallei* and *Burkholderia mallei* to 35 antimicrobial agents. *J Antimicrob Chemother* 54: 1134–1138.
8. Leelarasamee A, Bovornkitti S, 1989. Melioidosis: review and update. *Rev Infect Dis* 11: 413–425.
9. Sarovich DS, Webb JR, Pitman MC, Viberg LT, Mayo M, Baird RW, Robson JM, Currie BJ, Price EP, 2018. Raising the stakes: loss of efflux pump regulation decreases meropenem susceptibility in *Burkholderia pseudomallei*. *Clin Infect Dis* 67: 243–250.
10. Jenney AW, Lum G, Fisher DA, Currie BJ, 2001. Antibiotic susceptibility of *Burkholderia pseudomallei* from tropical northern Australia and implications for therapy of melioidosis. *Int J Antimicrob Agents* 17: 109–113.
11. Kingsley PV, Arunkumar G, Tipre M, Leader M, Sathiakumar N, 2016. Pitfalls and optimal approaches to diagnose melioidosis. *Asian Pac J Trop Med* 9: 515–524.
12. Health and Safety Executive, 2013. *The Approved List of Biological Agents*. London, England: Crown Copyright.
13. The Australia Group, 2014. *The Australia Group Common Control List Handbook, Volume II: Biological Weapons-Related Common Control Lists*. Available at: <https://www.dfat.gov.au/publications/minisite/theaustraliagroupnet/site/en/controlisthandbooks.html>. Accessed October 18, 2019.
14. American Biological Safety Association, 2016. *Risk Group Database*. Available at: <https://my.absa.org/Riskgroups>. Accessed October 18, 2019.
15. Centers for Disease Control and Prevention, 2018. *Select Agents and Toxins List*. Available at: <https://www.selectagents.gov/selectagentsandtoxinslist.html>. Accessed October 18, 2019.
16. World Health Organization, 2004. *Laboratory Biosafety Manual*, 3rd edition. Geneva, Switzerland: WHO.
17. Joint Technical Committee CH-026 SiL, 2010. *Safety in Laboratories. Part 3: Microbiological Safety and Containment*. Sydney, Australia: SAI Global Limited, 44–49.
18. Hoffmaster AR et al., 2015. Melioidosis diagnostic workshop, 2013. *Emerg Infect Dis* 21: e141045.
19. Mishra A, Shamshavali K, Sanathan SR, Rao SB, Talal B, Sravanthi R, 2017. Challenges in the diagnosis and treatment of melioidosis: a review. *Eur J Pharm Med Res* 4: 226–232.
20. West TE, Frevert CW, Liggitt HD, Skerrett SJ, 2008. Inhalation of *Burkholderia thailandensis* results in lethal necrotizing pneumonia in mice: a surrogate model for pneumonic melioidosis. *Trans R Soc Trop Med Hyg* 102 (Suppl 1): S119–S126.
21. Kovacs-Simon A, Hemsley CM, Scott AE, Prior JL, Titball RW, 2019. *Burkholderia thailandensis* strain E555 is a surrogate for the investigation of *Burkholderia pseudomallei* replication and survival in macrophages. *BMC Microbiol* 19: 97.
22. Haraga A, West TE, Brittnacher MJ, Skerrett SJ, Miller SI, 2008. *Burkholderia thailandensis* as a model system for the study of the virulence-associated type III secretion system of *Burkholderia pseudomallei*. *Infect Immun* 76: 5402–5411.
23. Propst KL, Mima T, Choi KH, Dow SW, Schweizer HP, 2010. A *Burkholderia pseudomallei* deltapurM mutant is avirulent in immunocompetent and immunodeficient animals: candidate strain for exclusion from select-agent lists. *Infect Immun* 78: 3136–3143.
24. Ginther JL, Mayo M, Warrington SD, Kaestli M, Mullins T, Wagner DM, Currie BJ, Tuanyok A, Keim P, 2015. Identification of

- Burkholderia pseudomallei* near-neighbor species in the Northern Territory of Australia. *PLoS Negl Trop Dis* 9: e0003892.
25. Tuanyok A et al., 2017. *Burkholderia humptydooensis* sp. nov., a new species related to *Burkholderia thailandensis* and the fifth member of the *Burkholderia pseudomallei* complex. *Appl Env Microbiol* 83: e02802-16.
 26. De Smet B et al., 2015. *Burkholderia stagnalis* sp. nov and *Burkholderia territorii* sp. nov., two novel *Burkholderia cepacia* complex species from environmental and human sources. *Int J Syst Evol Micr* 65: 2265–2271.
 27. Limmathurotsakul D et al., 2013. Systematic review and consensus guidelines for environmental sampling of *Burkholderia pseudomallei*. *PLoS Negl Trop Dis* 7: e2105.
 28. Mayo M, Kaesti M, Harrington G, Cheng AC, Ward L, Karp D, Jolly P, Godoy D, Spratt BG, Currie BJ, 2011. *Burkholderia pseudomallei* in unchlorinated domestic bore water, tropical northern Australia. *Emerg Infect Dis* 17: 1283–1285.
 29. Currie BJ, Price EP, Mayo M, Kaestli M, Theobald V, Harrington I, Harrington G, Sarovich DS, 2015. Use of whole-genome sequencing to link *Burkholderia pseudomallei* from air sampling to mediastinal melioidosis, Australia. *Emerg Infect Dis* 21: 2052–2054.
 30. Dutta S, Haq S, Hasan MR, Haq JA, 2017. Antimicrobial susceptibility pattern of clinical isolates of *Burkholderia pseudomallei* in Bangladesh. *BMC Res Notes* 10: 299.
 31. Inglis TJ, Rodrigues F, Rigby P, Norton R, Currie BJ, 2004. Comparison of the susceptibilities of *Burkholderia pseudomallei* to meropenem and ceftazidime by conventional and intracellular methods. *Antimicrob Agents Chemother* 48: 2999–3005.
 32. Podin Y et al., 2014. *Burkholderia pseudomallei* isolates from Sarawak, Malaysian Borneo, are predominantly susceptible to aminoglycosides and macrolides. *Antimicrob Agents Chemother* 58: 162–166.
 33. Fisher MW, Hillegas AB, Nazeeri PL, 1971. Susceptibility in vitro and in vivo of *Pseudomonas pseudomallei* to rifampin and tetracyclines. *Appl Microbiol* 22: 13–16.
 34. Dance DA, Wuthiekanun V, Chaowagul W, White NJ, 1989. The antimicrobial susceptibility of *Pseudomonas pseudomallei*. Emergence of resistance in vitro and during treatment. *J Antimicrob Chemother* 24: 295–309.
 35. Vorachit M, Chongtrakool P, Arkomsean S, Boonsong S, 2000. Antimicrobial resistance in *Burkholderia pseudomallei*. *Acta Trop* 74: 139–144.
 36. Scarff JM et al., 2019. Aminomethyl spectinomycins: a novel antibacterial chemotype for bioterror pathogens. *J Antibiot (Tokyo)* 72: 693–701.
 37. Cockerill F, Wikler M, Alder J, Dudley M, Eliopoulos G, Ferraro M, Hardy D, Hecht D, Hindler J, Patel J, 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard. *Clin Lab Stand Inst* 32: M07–A9.
 38. R Core Team, 2020. *R: A Language and Environment for Statistical Computing*. Vienna, Austria: R Foundation for Statistical Computing. Available at: <https://www.R-project.org/>.
 39. Medicines for Malaria Venture, 2018. *Pathogen Box Supporting Information*. Available at: <https://www.mmhv.org/mmv-open/pathogen-box/pathogen-box-supporting-information>. Accessed September 9, 2019.
 40. David J, Bell RE, Clark GC, 2015. Mechanisms of disease: host-pathogen interactions between *Burkholderia* species and lung epithelial cells. *Front Cell Infect Microbiol* 5: 80.
 41. Sawana A, Adeolu M, Gupta RS, 2014. Molecular signatures and phylogenomic analysis of the genus *Burkholderia*: proposal for division of this genus into the emended genus *Burkholderia* containing pathogenic organisms and a new genus *Paraburkholderia* gen. nov. harboring environmental species. *Front Genet* 5: 429.
 42. Paganin P, Tabacchioni S, Chiarini L, 2011. Pathogenicity and biotechnological applications of the genus *Burkholderia*. *Cent Eur J Biol* 6: 997–1005.
 43. Sahl JW et al., 2016. The effects of signal erosion and core genome reduction on the identification of diagnostic markers. *mBio* 7: e00846-16.
 44. Ross BN, Myers JN, Muruato LA, Tapia D, Torres AG, 2018. Evaluating new compounds to treat *Burkholderia pseudomallei* infections. *Front Cell Infect Microbiol* 8: 210.